Erratum: Effective combinatorial immunotherapy for castration-resistant prostate cancer (Nature (2017) 543 (728-732) DOI: 10.1038/nature21676);Effective combinatorial immunotherapy for castration-resistant prostate cancer

Nature

Volumn 543, Issue 7647, 2017, Pages 728-732

  Lu, Xin ^a,c   Horner, James W ^a   Paul, Erin ^a   Shang, Xiaoying ^a   Troncoso, Patricia ^a   Deng, Pingna ^a   Jiang, Shan ^a   Chang, Qing ^a   Spring, Denise J ^a   Sharma, Padmanee ^a   Zebala, John A ^b   Maeda, Dean Y ^b   Wang, Y Alan ^a   Depinho, Ronald A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b SYNTRIX BIOSYSTEMS INC   (United States)

^c UNIVERSITY OF NOTRE DAME   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CABOZANTINIB; CD11B ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACTOLISIB; DASATINIB; GAMMA INTERFERON; IMMUNE CHECKPOINT BLOCKING AGENT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 2; PHOSPHATIDYLINOSITOL 3 KINASE; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG; ANILIDE; CYTOKINE; IMIDAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; QUINOLINE DERIVATIVE;

ANDROGEN; ANTIGEN; CANCER; CELLS AND CELL COMPONENTS; GENE EXPRESSION; LIGAND; PROTEIN; RODENT; TUMOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INFILTRATION; CANCER RESISTANCE; CASTRATION RESISTANT PROSTATE CANCER; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; HUMAN TISSUE; IMMUNE EVASION; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MICROMETASTASIS; MOUSE; MYELOID-DERIVED SUPPRESSOR CELL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHIMERA; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; FEMALE; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROCEDURES; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SIGNAL TRANSDUCTION; TUMOR ASSOCIATED LEUKOCYTE;

ANILIDES; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CHIMERA; CYTOKINES; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; FEMALE; HUMANS; IMIDAZOLES; IMMUNOTHERAPY; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MICE; MOLECULAR TARGETED THERAPY; MYELOID-DERIVED SUPPRESSOR CELLS; PHOSPHATIDYLINOSITOL 3-KINASES; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PYRIDINES; QUINOLINES; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 85018869328     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature22348     Document Type: Erratum

References (43)

1. Watson, P. A., Arora, V. K. & Sawyers, C. L. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nature Rev. Cancer 15, 701-711 (2015).
2. Sharma, P. & Allison, J. P. The future of immune checkpoint therapy. Science 348, 56-61 (2015).
3. Kwon, E. D. et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, doubleblind, phase 3 trial. Lancet Oncol. 15, 700-712 (2014).
4. Beer, T. M. et al. Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. J. Clin. Oncol. 35, 40-47 (2017).
5. Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454 (2012).
6. Gabrilovich, D. I. & Nagaraj, S. Myeloid-derived suppressor cells as regulators of the immune system. Nature Rev. Immunol. 9, 162-174 (2009).
7. Vuk-Pavlovic, S. et al. Immunosuppressive CD14+HLA-DRlow/-monocytes in prostate cancer. Prostate 70, 443-455 (2010).
8. Brusa, D. et al. Circulating immunosuppressive cells of prostate cancer patients before and after radical prostatectomy: profile comparison. Int. J. Urol. 20, 971-978 (2013).
9. Hossain, D. M. et al. TLR9-targeted STAT3 silencing abrogates immunosuppressive activity of myeloid-derived suppressor cells from prostate cancer patients. Clin. Cancer Res. 21, 3771-3782 (2015).
10. Di Mitri, D. et al. Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer. Nature 515, 134-137 (2014).
11. Wang, G. et al. Targeting YAP-dependent MDSC infiltration impairs tumor progression. Cancer Discov. 6, 80-95 (2016).
12. Shen, M. M. & Abate-Shen, C. Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev. 24, 1967-2000 (2010).
13. Ding, Z. et al. Telomerase reactivation following telomere dysfunction yields murine prostate tumors with bone metastases. Cell 148, 896-907 (2012).
14. Ding, Z. et al. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature 470, 269-273 (2011).
15. Araujo, J. C. et al. Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol. 14, 1307-1316 (2013).
16. Smith, M. et al. Phase III study of cabozantinib in previously treated metastatic castration-resistant prostate cancer: COMET-1. J. Clin. Oncol. 34, 3005-3013 (2016).
17. Carver, B. S. et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 19, 575-586 (2011).
18. Jia, S. et al. Opposing effects of androgen deprivation and targeted therapy on prostate cancer prevention. Cancer Discov. 3, 44-51 (2013).
19. Peng, W. et al. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov. 6, 202-216 (2016).
20. Kim, K. et al. Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. Proc. Natl Acad. Sci. USA 111, 11774-11779 (2014).
21. Rivera, L. B. et al. Intratumoral myeloid cells regulate responsiveness and resistance to antiangiogenic therapy. Cell Reports 11, 577-591 (2015).
22. De Henau, O. et al. Overcoming resistance to checkpoint blockade therapy by targeting PI3K? in myeloid cells. Nature 539, 443-447 (2016).
23. Kaneda, M. M. et al. PI3K? is a molecular switch that controls immune suppression. Nature 539, 437-442 (2016).
24. Frick, A. et al. Immune cell-based screening assay for response to anticancer agents: applications in pharmacogenomics. Pharm. Genomics Pers. Med. 8, 81-98 (2015).
25. Schade, A. E. et al. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood 111, 1366-1377 (2008).
26. Tu, S. et al. Overexpression of interleukin-1? induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell 14, 408-419 (2008).
27. Ali, K. et al. Inactivation of PI(3)K p110? breaks regulatory T-cell-mediated immune tolerance to cancer. Nature 510, 407-411 (2014).
28. Costa, C. et al. Measurement of PIP3 levels reveals an unexpected role for p110? in early adaptive responses to p110?-specific inhibitors in luminal breast cancer. Cancer Cell 27, 97-108 (2015).
29. Muzumdar, M. D., Tasic, B., Miyamichi, K., Li, L. & Luo, L. A global doublefluorescent Cre reporter mouse. Genesis 45, 593-605 (2007).
30. Birbach, A. Use of PB-Cre4 mice for mosaic gene deletion. PLoS ONE 8, e53501 (2013).
31. Chen, Z. et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436, 725-730 (2005).
32. Benavides, F. et al. Microsatellite DNA variants between the inbred SENCAR mouse strains. Mol. Carcinog. 28, 191-195 (2000).
33. Saha, B. K. Typing of murine major histocompatibility complex with a microsatellite in the class II Eb gene. J. Immunol. Methods 194, 77-83 (1996).
34. Lu, X. et al. VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging ? 4? 1-positive osteoclast progenitors. Cancer Cell 20, 701-714 (2011).
35. Asangani, I. A. et al. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature 510, 278-282 (2014).
36. Maira, S.-M. et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol. Cancer Ther. 7, 1851-1863 (2008).
37. Nguyen, H. M. et al. Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling. PLoS ONE 8, e78881 (2013).
38. Vitali, R. et al. Activity of tyrosine kinase inhibitor dasatinib in neuroblastoma cells in vitro and in orthotopic mouse model. Int. J. Cancer 125, 2547-2555 (2009).
39. Nair, A. B. & Jacob, S. A simple practice guide for dose conversion between animals and human. J. Basic Clin. Pharm. 7, 27-31 (2016).
40. Fazio, N. et al. A phase II study of BEZ235 in patients with everolimus-resistant, advanced pancreatic neuroendocrine tumours. Anticancer Res. 36, 713-719 (2016).
41. Carlo, M. I. et al. A phase Ib study of BEZ235, a dual inhibitor of phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR), in patients with advanced renal cell carcinoma. Oncologist 21, 787-788 (2016).
42. Bjornson, Z. B., Nolan, G. P. & Fantl, W. J. Single-cell mass cytometry for analysis of immune system functional states. Curr. Opin. Immunol. 25, 484-494 (2013).
43. Yuen, A. K. L. & Hutton, C. A. Deprotection of pinacolyl boronate esters via hydrolysis of intermediate potassium trifluoroborates. Tetrahedr. Lett. 46, 7899-7903 (2005).